ClearPath Development Co. has partnered with Astellas Pharma Inc. to form a second vaccine company, Nosocomial Vaccine Corp. (NVC).
The two companies launched their first vaccine company, RSVC Corp., in 2013.
"Together with our collaborators at Affinivax and the University of Maryland School of Medicine, we are accelerating research and development of a vaccine for important pathogens causing nosocomial infections, one of the most common (hemagglutination inhibition) HAIs," NVC Chief Executive Officer Donna Ambrosino said. "HAIs are a significant global health concern, with the Centers for Disease Control and Prevention estimating that more than 1.9 million patients per year in the United States will contract a bacterial nosocomial infection in medical facilities, including ambulatory surgical centers, hospice centers, nursing homes and rehabilitation centers."
Presently, no vaccine is available for any of the major nosocomial pathogens.
"This is an important area of unmet medical need," George Siber, ClearPath's chief scientific officer, said.
For more information, visit www.clearpathdevco.com.